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1. Introduction
1.1. Health impact of cardiovascular disease (CVD)
Cardiovascular  disease  (CVD)  is  the  principal  cause  of  death  worldwide,  representing
nearly 30% of the annual global mortality and 10% of global health burden [1]. The cur‐
rent  status of  CVD is  now on international  scale;  which can be considered as  the com‐
monest  chronic  illness  in  both  developed  and  developing  countries,  causing  the  most
deaths and the greatest impact on morbidity [2]. In 2006, CVD was the leading cause of
death  for  Canadians,  representing  30% of  all  deaths  [3].  A  total  number  of  1.3  million
Canadians are diagnosed having heart disease accounting for 5% among those above 12
years  and  23% at  75  years  and  older.  The  increased  rate  of  obesity  and  diabetes  com‐
bined with further aging of the population will likely lead to an increase in the number
of people with CVD in the future. This will  compromise the health of Canadians, put a
strain on the health care system, and have a significant economic impact on Canada [4].
Similarly, over the past five decades the prevalence of CVD has steadily increased in eco‐
nomically developing countries [5]. These countries will account for 76% of an estimated
25 million death  due to  CVD in  2020  [6].  On an international  basis,  by  2020  CVD will
reach nearly epidemic proportions and become the cause of more deaths,  disability and
economic loss than any others group of diseases.  The number of  fatalities by CVD pro‐
jected to increase to over 20 million a year by 2020 and over 24 million a year by 2030
[7]. Apparently, understanding the aetiology of CVD and accordingly develop preventive
and therapeutic approaches to address this health threat continues to be critically impor‐
tant  in  the  next  decades although significant  achievements  have been made in  the past
decades.
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2. Risk factors of CVD
The aetiology of CVD is multifactorial, complex and still not completely understood. However,
there is now a general agreement that elevated total cholesterol, LDL-cholesterol and triacyl‐
glycerol levels, low HDL-cholesterol concentrations, smoking, high blood pressure, hyper‐
glycemia and diabetes are all risk factors of CVD. Physical inactivity, obesity, diet and low
socio-economic status are thought to be predisposing risk factors which work, at least in part,
as promoter on other risk factors. These factors predispose to develop syndrome X or metabolic
syndrome, which is characterised by obesity, hypertension, dyslipoproteinaemia, and
disturbed glucose tolerance [8]. Some other factors such as elevated prothrombotic factors,
markers of inflammation, elevated homocysteine, elevated lipoprotein (a) and some psycho‐
logical factors show associations with CVD [6]. Nevertheless, the aetiology of CVD is far from
clear [9], and most factors are unmodifiable while others can be modified through the change
of diet habits and lifestyles.
2.1. Unmodifiable risk factors
2.1.1. Ageing
Cardiovascular diseases, such as atherosclerosis, coronary heart disease and resultant heart
failure reach epidemic proportions among older persons. Aging leads to arterial stiffening that
results in aortic dilation and wall thickening along with increased collagen level. Potential age-
associated changes in the tissue levels or responses to growth factors, catecholamines,
angiotensin II, endothelin tumor growth factors β ( TGF β) or fibroblast growth factors
influences myocardial or vascular cells. Deficit in myocardial beta adregenic receptor signal‐
ling, decline in omega-3 polyunsaturated fatty acids and increased reactive oxygen species
generation occur with aging, which enhances Ca2+ influx [10]. The clinical manifestations and
prognosis of CVD and resultant heart failure worsen with ageing. Over 83 percent of people
who die of coronary heart disease are 65 or older. Thus, age, per se, is the major risk factor for
CVD [10].
2.1.2. Gender
There is a marked difference in CVD risk between sexes [11]. Incidence of CVD was approxi‐
mately 3-fold and mortality about 5-fold greater in men thanin women [12]. Among middle-
aged people,incidence of coronary heart disease is 2 to 5 times more in men than in women,
and this sexratio varies between populations. The role of major risk factors such as lipid
abnormalities, high blood pressure, smoking, obesity and diabetes in the development of CVD
is well established amongmen (Jousilahti, Vartiainen et al. 1999). In women, significnat shift
in their physiological function and heath profiles occurs during and the postmenopausal.
When entering into middle ages, women tend to have lower LDL cholesterol and higher HDL
cholesterol values than men of similar age. Following menopause, total cholesterol, LDL
cholesterol and triglycerides levels increases while HDL levels remain unchanged or decrease
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slightly. These alterations in lipid values are thought to be related in part to loss of protective
effects of estrogen [13].
2.1.3. Heredity (including race)
The prevalence of CVD considerably varies by race/ ethnicity. Genetic predispositions are a
result of gene mutations, which alter the biological function expressed by the original genes
(polymorphisms) and increases an individual risk for the disease. Several polymorphism and
linkage markers have been identified as being correlated to the onset of CVD. For example,
M235T polymorphism of the angiotensinogen gene is linked to hypertension and later to the
development of CVD [14]. In many developed countries, racial and ethnic minorities bear
disproportionate burden of heart disease. Significant differences in socioeconomic status and
conventional heart disease risk factors exist among racial/ethnic groups in the United States,
Canada and United Kingdom (Ludwig, Ebbeling et al. 2002). The rate of heart disease among
the racial and ethnic group in the United States vary widely, with African Americans having
rates a half to three fold greater than Asians, depending on the gender [15]. It is also well
documented that the prevalence of CVD is higher in several minority populations (Hispanics
and African Americans) in comparison to whites. [16]. However, these differences do not fully
account for the observed disparities in disease prevalence, suggesting the presence of other
biological factors [17].
2.2. Modifiable risk factors
2.2.1. Obesity
Obesity is an independent risk factor for CVD. It is a chronic metabolic disorder associat‐
ed  with  increased  morbidity  and  mortality.  Obesity  may  affect  atherosclerosis  through
many risk factors such as dyslipidemia, hypertension, glucose intolerance, and increased
chronic  inflammatory  and prothrombotic  state.  Obesity  causes  a  variety  of  adaptations/
alterations  in  cardiac  structure  and  function  due  to  excessive  adipose  tissue  accumula‐
tion,  even in the absence of  comorbidities  [18].  Thus,  it  increases cardiac workload that
leads to heart failure,  coronary heart disease,  sudden cardiac death,  and arterial  fibrilla‐
tion  [19].  In  many cases,  these  events  result  in  mortality  and morbidity.  By  favourably
modifying blood lipids,  in  particular  LDL cholesterol,  lowering blood pressure,  control‐
ling blood sugar,  decreasing proinflammatory cytokines and adhesion molecules,  weight
loss  may prevent  the progression of  atherosclerosis  or  the occurrence of  acute coronary
heart events in the obese high-risk populations [18].
2.2.2. High blood cholesterol
A high concentration of serum cholesterol is a major risk factor for coronary heart disease [20].
The relationship between abnormal plasma cholesterol fractions and increased CVD risk was
described 60 years ago [21]. The excessive cholesterol, especially cholesterol transported/
carried by low density lipoproteins that contain protein apolipoprotein (apo) B100 contributes
to the formation of atherosclerotic plaques in arteries. Accordingly, cholesterol that is carried
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by LDL particles is called “bad cholesterol”. by contrast, HDL cholesterol which transports
esterified cholesterol from the periphery to the liver is considered more cardioprotective and
sometimes referred to as “good cholesterol” [22]. The ratio of LDL to HDL cholesterol is more
important than LDL or HDL cholesterol concentration and has been widely used to evaluate
susceptibility to the development of heart disease. For a healthy person, it is recommended to
maintain the LDL/HDL ratio below 3.5.
2.2.3. High blood pressure
Hypertension is a highly prevalent major contributor to atherosclerotic cardiovascular disease.
It accelerates atherogenesis, imparting a 2- to 3-fold coronary heart disease (CHD) and lethal
sequel [23]. In most cases, hypertension results from excessive vasoconstriction of the small
arterioles throughout the body, raising the diastolic pressure. Because of high peripheral
resistance, the heart needs to generate more force to overcome the resistance created by the
constricted arterioles and supply adequate blood to the tissues, which leads to a compensatory
rise in systolic blood pressure. This excess of systolic and diastolic blood pressures causes
excessive vasoconstriction. Thus, increased levels of systolic and diastolic blood pressure are
associated with an increased risk of CVD events [24]. When high blood pressures co-exist with
obesity, smoking, hypercholesterolemia, and/or diabetes, the risk of heart attack and stroke
increases several times.
2.2.4. Physical inactivity
Sedentary lifestyle is associated with almost twice the risk of developing coronary heart disease
compared with their active counterparts. Regular physical activity plays a crucial role in the
prevention of CVD. High levels of physical activity are associatedwith substantial reductions
in CVD risk, and total mortalitydecreases by 20% to 30% for the increase of every 1000
kcal/wk of energy expenditure resulting from physical activity [25]. Regular exercise has a
favourable effect on many of the establishedrisk factors of CVD. Exercisepromotes weight
reduction, reduce blood pressure, "bad” cholesterol (LDL level), and total cholesterol,and can
raise the "good" cholesterol (HDL) [26].
2.2.5. Diabetes mellitus
Diabetes has long been recognized to be an independent riskfactor for CVD. Type-1 dia‐
betes ortype-2 diabetes is at high risk for several cardiovasculardisorders: coronary heart
disease,  stroke,  peripheral  arterialdisease,  cardiomyopathy,  and congestive  heart  failure.
Closely linked to type-2 diabetes are several metabolic risk factors such as hypertension,
atherogenic  dyslipidemia which is  associated with insulin resistance that  relatedto coro‐
nary  heart  disease.  Cardiovascularcomplications  are  now  the  leading  causes  of  illness
and  death  in  the  diabetic  patient.  The  incidence  of  diabetes  rises  with  advancing  age,
obese and overweight persons and in the populations (race/ethnicity) who areparticularly
susceptible to diabetes [27].
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2.2.6. Tobacco smoke
Smokingnearly doubles the risk of heart disease. Smoking acts synergisticallywith other risk
factors, substantially increasing the risk ofCVD [28]. The exact toxic componentsof cigarette
smoke and the mechanisms involved in smoking-relatedcardiovascular dysfunction are
notclearly elucidated, but smoking increasesinflammation, thrombosis, and oxidation of
LDLcholesterol. Smokers have significantly higherserum total cholesterol, LDL cholesterol
and triacylglycerol levels, while having lower blood concentration of HDL cholesterol than
non-smokers [29]. Cigarette smoke exposure increases oxidativestress as a potential mecha‐
nism for initiating cardiovasculardysfunction. Cigarette smoke exposure decreases the plasma
activity of paraoxonase, an enzymethat protects against LDL oxidation. Smoking is also found
to be an independent predictor of newcoronary lesion formation and thrombosis [30].
In spite of identification of many unmodifiable and modifiable risk factors, there are still
several paradoxes in the pathogenesis of CVD that cannot be sufficiently explained; mortality
from CVD is relatively low despite a high intake of saturated fatty acids [31] or a high incidence
of CVD without having the expected risk indicators [32]. CVD mortality rate in urban popu‐
lations is higher compared with rural populations despite a very low fat intake [33]. All these
paradoxes support the assumption that some important factors in the aetiology of CVD are
currently unknown. However, it has been well established that elevated blood total cholesterol,
especially LDL cholesterol levels is one of the primary risk factors that contribute to the
development of atherosclerosis and ultimately CVD. Therefore, in the following sections, we
focus mainly on the atherosclerosis, cholesterol metabolism and homeostasis, benefits versus
side effects of current cholesterol-lowering products, and our perspectives on the development
of future cholesterol-lowering products.
3. Atherosclerosis and CVD
Atherosclerosis is a disease of the arterial wall that is characterized by cholesterol accumulation
and culminates in potentially life-threatening conditions such as heart attack, stroke and
angina. The build-up of cholesterol in the walls of arteries is a hallmark of atherosclerosis.
However, the process starts is poorly understood. The atherogenic process starts at an early
age with the deposition in blood vessel walls of lipids such as cholesterol, derived from
lipoproteins circulating in the bloodstream, which leads to the formation of the characteristic
'fatty streaks'. Inflammatory white blood cells congregate at these damaged areas through their
interaction with adhesion molecules expressed by cells in the endothelial layer, which lines
the inside of blood vessels. This event then sets off a cascade of inflammatory process and
further lipid deposition, leading eventually to full blown atherosclerosis with plaque forma‐
tion in the artery wall. Atherosclerosis is thus viewed as a chronic inflammatory disease of the
blood vessel wall [34], [35]. Oxidized LDL contributes to atherogenesis and is an early event
of atherosclerosis. WhenLDL particles become trapped in an artery, they can undergoprog‐
ressive oxidation and be internalized by macrophages bymeans of the scavenger receptors on
the surfaces of these cells. The internalization leads to the formation of lipid peroxidesand
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facilitates the accumulation of cholesterol esters, resultingin the formation of foam cells. As
the fatty streak progresses, smooth muscle cells (not normally present in the subendothelial
space) migrate from the media to the subendothelial space where they proliferate and produce
connective tissue to form a fibrous cap, which represents the second phase of atherosclerosis.
Finally, complicated lesions occur, which can manifest calcification, hemorrhage, ulceration
and thrombosis [35, 36]. All these changes and events lead to the hardening and thickening of
artery wall, reducing or blocking blood flow. Atherosclerosis is a silent and asymptomatic
disease until complications arise with thrombosis and occurrence of clinical symptoms [37].
The clinical manifestation of atherosclerotic plaque formation is acute vascular occlusion due
to the formation of a thrombus or clot which can lead to ischemia of vital organs, such as heart
causing myocardial infarction, brain resulting in strokes and lower extremites causing
peripheral artery disease. Oxidized LDL contributes to atherothrombosis by inducing endo‐
thelial cell apoptosis, and thus plaque erosion, by impairing the anticoagulant balance in
endothelium, stimulating tissue factor production by smooth muscle cells, and inducing
apoptosis in macrophages [38]. It is reasonably thinking that maintaining a healthy cholesterol
or lipid profile is critically important to the health cardiovascular system.
4. Cholesterol homeostasis
Cholesterol, the characteristic steroid alcohol of animal tissues, performs a number of essential
functions in the body. For example, cholesterol is a structural component of cell membranes
and modulates cell membrane fluidity; cholesterol is a precursor of bile acids, steroid hormones
and vitamin D. It is therefore of critical importance that the cells of the body be assured a
continuous supply of cholesterol. To meet this need, a complex series of transport, biosynthetic
and regulatory mechanism has evolved. The liver plays a central role in the regulation of the
body’s cholesterol homeostasis. For example, cholesterol enters the liver’s cholesterol pool
from a number of sources including dietary cholesterol, as well as cholesterol synthesized de
novo by extra hepatic tissues as well as by the liver itself. Cholesterol is eliminated from the
liver as unmodified cholesterol in the bile or it can be converted to bile acids that are secreted
in bile into the intestinal lumen.
Cholesterol, similar with other lipids (triacylglycerols and phospholipids) do not circulate
as independent molecules but  are carried by specific  apolipoproteins to form macromo‐
lecular  complexes,  called  lipoproteins.  Plasma  lipoproteins  keep  their  component  lipids
soluble during circulation and provide an efficient mechanism for transporting their lipid
contents  to  (and from) the  tissues.  Four  major  groups of  lipoproteins  have been identi‐
fied and they are important physiologically and in clinical  diagnosis.  They are chylomi‐
crons,  very  low  density  lipoproteins  (VLDL  or  pre  β  lipoprotein),  LDL  (β  lipoprotein)
and HDL (α lipoprotein). They differ in their relative composition of cholesterol, triacyl‐
glyceroles, phospholipids and apoproteins.
Chylomicrons,  the  largest  and least  dense  lipoproteins,  predominately  transport  triacyl‐
glycerols to adipose tissue and muscle, but also deliver the absorbed dietary and billiary
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cholesterol to the liver. Once most of the triacylglycerols have been delivered to the adi‐
pose tissue and muscle, the remnants of the lipoprotein, including cholesterol, apo-E, and
apo-B48 are then delivered to and taken up by the liver through interaction with the chy‐
lomicron remnant receptor.
VLDL is smaller and more dense than chylomicrons. VLDL contains triacylglycerols, some
cholesterol and cholesteryl esters and the apoproteins; apo-B100, apo-CI, apo-CII, apo-CIII,
and apoE. VLDL delivers triacylglycerols and cholesteryl esters from the liver and distribute
them throughout the body. When VLDL moves into the circulating blood, it is converted first
to intermediate density lipoproteins (IDL) and then into low density lipoproteins (LDL).
Lipoprotein lipase serves to remove the majority of fatty acids from both the VLDL and IDL,
thus increasing the density of the lipoproteins while maintaining cholesterol and cholesteryl
ester concentrations. The removal of fatty acids and the loss of all apolipoproteins except
apoB-100 and apo(a) results in the formation of LDL.
LDL  is  the  primary  blood  carrier  of  cholesterol  and  delivers  cholesterol  to  all  tissues.
LDL can be  absorbed by the  liver  and other  tissues  via  receptor  mediated endocytosis.
The LDL receptor recognizes the main apolipoprotein of LDL, apo-B100, resulting in the
intake of LDL and subsequently enzymatic hydrolysis of cholesteryl ester. A positive cor‐
relation exists between the incidence of coronary atherosclerosis and the plasma concen‐
tration of LDL cholesterol.
High density lipoprotein is the smallest but most dense lipoproteins in the body. Nascent HDL
or HDL contains several types of apolipoproteins including apo-AI, II & IV, apo-CI, II & III,
apoD and apoE. HDL contains protein, phospholipids, cholesteryl esters, and cholesterol. HDL
is produced as a protein-rich particle in the liver and intestine, and serves as a circulating
source of Apo-CI & II and ApoE proteins. The HDL protein particle accumulates cholesteryl
esters through the esterification of cholesterol by lecithin:cholesterol acyl-transferase (LCAT).
LCAT is activated by apo-AI on HDL. HDL returns the liver where cholesterol is removed by
reverse cholesterol transport, thus, serving as a scavenger of free cholesterol. Cholesteryl ester
transfer protein (CETP) facilitates the transfer of cholesteryl esters from HDL to VLDL, IDL,
and LDL in exchange of triacylglycerol, relieving the inhibition of LCAT activity in HDL.
5. Hyperlipidemia and causes
Hyperlipidemia, most common form of dyslipidemia, refers to elevation of lipoproteins and/
or lipids. HDL, LDL, and VLDL vary in their atherogenicities. High levels of cholesterol
particularly LDL cholesterol together with low levels ofHDL cholesterol increase the risks for
developing atherosclerosis [39]. Hyperlipidemia itself usually causes no symptoms but can
lead to the development of symptomatic vascular disease, including coronary artery disease
and peripheral arterial disease. There are two different types of hyperlipidemia, primary and
secondary hyperlipidemia:
1. Primary hyperlipidemia is generally due to genetic causes, such as a mutation in a receptor
or binding protein. This type of hyperlipidemia is often linked to family history. For
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instance, defects in the essential components of lipid transportation and metabolism
inherited from family. Examples include familial defect in LDL receptor or apo B-100
(diminished LDL clearance and hypercholesterolemia), familial lipoprotein lipase
deficiency (hypertriglyceridemia), and combination of multiple unknown defect and
known familial defects (combined hyperlipidemia).
2. Secondary hyperlipidemia arises due to other underlying causes, such as sedentary
lifestyle coupled with the excessive dietary intakes of saturated fat, cholesterol and trans-
fats, in addition to many other disease conditions and drug uses. These factors include
obesity, diabetes mellitus, hyperhomocystinemia, smoking, alcohol intake, chronic
kidney disease, hypothyroidism, primary biliary cirrhosis and other cholestatic liver
diseases, and drugs, such as thiazides, β-blockers, retinoids, estrogen and progesterons,
and glucocorticoids.
6. Metabolic pathways involved in cholesterol homeostasis
6.1. Biosynthesis
Cholesterol levels in the body derived from de novo biosynthesis and diet. The majority of
cholesterol utilized by healthy adults is synthesized in the liver, which accounts for about 70%
of the daily cholesterol. Virtually all cells containing nucleus are capable of cholesterol
synthesis, which occurs in endoplasmic reticulum and the cytosol. Biosynthesis of cholesterol
generally takes place in the endoplasmic reticulum of hepatic cells and begins with acetyl-CoA,
which is mainly derived from fatty acid oxidation reaction in the mitochondria. The conversion
of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) to mevalonate by HMG-CoA reductase is
the rate-limiting step of cholesterol biosynthesis and is under strict regulatory control. Thus,
HMG-CoA reductase is one of important targets of cholesterol lowering drugs. The develop‐
ment of statin drugs is a very successful story of discovering and applying HMG-CoA
reductase inhibitor to lower hypercholesterolemia.
6.2. Absorption
Dietary cholesterol is absorbed within the lumen of the small intestine. Bile salts produced
from cholesterol in the liver interact with phospholipids to produce a biliary micelle that is
transported via bile into the lumen. Dietary cholesterol in the lumen is easily incorporated into
the micelles and together with the biliary cholesterol can be absorbed into the enterocytes. In
the enterocytes, absorbed cholesterol is esterified by acyl-coenzyme A:cholesterol acyltrans‐
ferase 2 (ACAT2), which is found in both the intestine and liver. Reducing the absorption of
cholesterol of dietary ad billiary sources has become another key area in cholesterol research
and product development. A typical example is plant sterols/stanols that have long found as
effective inhibitors of cholesterol absorption. These molecules inhibit cholesterol absorption
by competitively inhibiting with cholesterol for incorporation into micelles. Recently, inhibi‐
tors, such as ezetimibe, that block the absorption of cholesterol into the enterocytes through
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suppressing the activity of cholesterol transporters have also been used to reduce absorption
of dietary cholesterol.
6.3. Transport
Chylomicrons deliver absorbed dietary and biliary cholesterol from the enterocytes to the
liver.  During  the  process,  triacylglycerols  are  released  with  assistance  of  lipoprotein  li‐
pase and taken up by adipose tissues and muscle,  the remnants of  the lipoprotein then
delivered to,  and taken up by,  the  liver  through interaction with the  chylomicron rem‐
nant  receptor.  In  the  liver,  absorbed  cholesterol,  together  with  synthesized  cholesterol
and cholesterol transported back from peripheral tissues and LDL receptor-mediated up‐
take  go  through  several  metabolic  pathways  and  secreted  out  from  different  outputs.
One of them is the secretion in VLDL back into the bloodstream. VLDL removes triacyl‐
glycerols and cholesteryl esters from the liver and distributes them throughout the body.
Endothelial  Lipoprotein  lipase  remove  the  majority  of  fatty  acids  from  both  the  VLDL
and IDL, thus increasing the cholesterol and cholesteryl ester concentrationsand apoB-100
results in LDL. LDL is the primary plasma carrier of cholesterol, which can be taken up
by the liver and other tissues via receptor-mediated endocytosis. The cytoplasmic domain
of LDL receptor facilitates the formation of coated pits which is the receptor-rich regions
of  the  membrane.  The  ligand  binding  domain  of  the  receptor  recognizes  apo-B100  on
LDL, resulting in the formation of a clathrin-coated vesicle that buds from the inner sur‐
face of the cell membrane. ATP-dependent proton pumps lower the pH inside the vesicle
resulting in dissociation of LDL from its receptor. After loss of the clathrin coat, the vesi‐
cles fuse with lysozomes, resulting in peptide and cholesteryl ester enzymatic hydrolysis.
On the other hand, HDL is the small and rich in lipoproteins. The HDL protein particle
accumulates cholesteryl esters by the esterification of cholesterol with lecithin:cholesterol
acyl-transferase  (LCAT).  In  the  plasma,  these  particles  undergo  aseries  of  remodeling
steps  involving  two  HDL-associated  proteins:phospholipid  transfer  protein  (PLTP)  and
CETP.  The  primary  role  of  PLTP  is  in  thetransfer  of  surface  remnants,  which  contain
apolipoproteinsand phospholipids originating from triglyceride-rich lipoproteins,to pre-ß–
HDL.  PLTP  has  also  been  implicatedin  mediating  fusion  of  HDL  particles  to  generate
pre-ß–HDLand CE-rich HDL. CETP promotesboth transfer and exchange of hydrophobic
lipids,  CE,  and triacylglycerols  between lipoproteins.  HDL can acquire  cholesterol  from
cell  membranes and transfer cholesteryl esters to VLDL and LDL via the transferase ac‐
tivity  of  apoD.  More  importantly,  HDL can  return  to  the  liver  where  cholesterol  is  re‐
moved by reverse  cholesterol  transport,  thus  serving as  a  scavenger  of  free  cholesterol.
Scavenging  activity  of  HDL  initiates  by  accepting  cholesterol  from  tissues  in  smaller
HDL3  via  the  ATP-binding  Cassette  transporter  -1  (ABC-1).  The  cholesterol  in  HDL3  is
then esterified by LCAT, increasing the size of the particles to form the less dense HDL2.
The cycle is completed by the reformation of HDL3  either after selective delivery of cho‐
lesteryl  esters  to  the  liver  via  the  scavenger  receptor-B1  or  by  the  hydrolysis  of  HDL2
phospholipid and triacylglycerol by hepatic lipase. HDL2  concentration is inversely relat‐
ed to the incidence of coronary atherosclerosis.  The enzyme cholesterol esterase controls
A New Perspective on the Development of Cholesterol-Lowering Products
http://dx.doi.org/10.5772/54729
189
the hydrolysis of these stored cholesterol esters, yielding bioavailable cholesterol and fat‐
ty acids.
6.4. Excretion of cholesterol
About 1 g of cholesterol is eliminated from the body per day, approximately equivalent to the
amount that absorbed cholesterol and synthesize cholesterol. Approximately, half is excreted
in the feces after conversion to bile acids in liver, and the remainder is excreted as cholesterol.
Bile acids serve to remove unwanted cholesterol from the body and to aid in lipid digestion
in the intestine. 7α-hydroxylase, the rate limiting enzyme of bile acid biosynthesis converts
cholesterol into 7-hydroxycholesterol. 7-hydroxycholesterol is converted to one of the two
primary bile acids, cholic acid and chenodeoxycholic acid. Bile acids are then delivered to the
intestines where they aid in the absorption of lipids. Some of bile acids are modified to form
secondary bile acids (lithocholic acid and deoxycholic acid) in the intestine by intestinal
bacteria. However, the majority of bile acids delivered to intestine are recycled by re-absorp‐
tion in the ileum and returned to the liver by enterohepatic circulation. In liver, glyco- and
tauroconjugate bile acids are formed and stored in gall bladder, from where they are released
into the intestinal lumen for aid fat/lipids digestion and absorption.
7. Regulation of specific pathways and its influence on cholesterol
homeostasis
Blood cholesterol concentration is a result of balance between cholesterol input and cholesterol
output. When the input is surpass the output, blood cholesterol increases and by contrast,
when cholesterol input is less than the output blood cholesterol levels decrease. Cholesterol
input is attributed from the intestinal absorption of dietary and biliary cholesterol and
cholesterol biosynthesis. On the other hand, the cholesterol output is mainly from LDL-
receptor mediated LDL-cholesterol clearance, reverse transport by HDL, cholesterol catabo‐
lism by converting into bile acids, cholesterol and bile acids secretion in bile into the intestine
lumen, and fecal excretion.
Metabolic nuclear receptors serve a central role in maintainingcellular and whole-body
cholesterol homeostasis [40]. Two important transcriptional mechanisms to regulate choles‐
terol metabolism are the pathways mediated by sterol responsive element– binding protein
(SREBP) and liver X receptor (LXR), which tightly regulate intracellular sterol concentrations.
The SREBP pathway ensures that there is sufficientcholesterol to meet cellular requirements
by directly activating expression of genesinvolved in the synthesis and uptake of cholesterol,
and lipogenesis [41]. In the setting ofexcess free or unesterified cholesterol, SREBP-depend‐
entgene expression is suppressed. LXR and farnesoid X receptor (FXR),together with other
members of the nuclear receptor superfamilypromote sterol storage, transport, and catabolism
to prevent cholesterol accumulation [42]. LXRs respond to elevated cholesterol levels via
transactivationof genes involved in sterol transport (ABCA1, ABCG1, ABCG5,and ABCG8),
cholesterol efflux and high-density lipoprotein(HDL) metabolism (ABCA1, APOE, CETP, and
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PLTP), and sterol catabolism(CYP7A1) [42]. Other members of metabolicnuclear receptor
family include receptors for bile acids (CAR and PXR), and fatty acids (peroxisome prolifer‐
aotr-activated receptors). Throughthe coordinated regulation of gene transcription, these
nuclearreceptors regulate the key aspects of cellular and whole-body sterolhomeostasis,
including cholesterol absorption and synthesis, lipoprotein synthesisand remodeling, lipo‐
protein uptake by peripheral tissues, reversecholesterol transport, and bile acid synthesis and
absorption.
The amount of cholesterol that is synthesized in the liver is tightly regulated by dietary
cholesterol levels. When dietary intake of cholesterol is high, synthesis is decreased and when
dietary intake is low, synthesis is increased. However, cholesterol produced in other tissues is
under no such feedback control. Cholesterol and similar oxysterols (the oxygenated deriva‐
tives of cholesterol, such as 22(R)-hydroxycholesterol, 2 4(S)-hydroxycholesterol, 27-hydrox‐
ycholesterol, and cholestenoic acid) act as regulatory molecules to maintain healthy levels of
cholesterol. In tissues, many factor influence cholesterol balance through every cholesterol
metabolic pathways.
7.1. LDL receptor-mediated cholesterol clearance
Cellular cholesterol increase is due to the uptake of cholesterol containing lipoproteins by
receptors. LDL receptor regulates the cellular transport of LDL particles. One mechanism for
regulating LDL receptor expression and controlling the expression of all the enzymes in the
cholesterol biosynthetic pathway involves sterol-sensitive response elements (SREs). SREs are
found in the promoters of the genes coding for the enzymes of cholesterol biosynthesis
pathway and LDL receptors. Transcription factors of SRE activation are SREBPs. Three major
SREBP isoforms, SREBP-1a, -1c, and -2, have been identified and differ in relative abundance
in the liver and other various tissues. SREBP-1a is a potent activator of all SREBP-responsive
genes and functions to maintain basal levels of cholesterol and fatty acid synthesis. SREBP-1c
selectively activates genes involved in fatty acid synthesis, while SREBP-2 preferentially
regulates genes important for cholesterol homeostasis by activating the transcription of HMG-
CoA synthase, HMG-CoA reductase, LDL receptor [41].
Due to their ability to bind SREs, SREBP-2 plays an instrumental role in cholesterol homeo‐
stasis. These transcription-regulatory proteins are bound by another protein called SREBP
cleavage activating proteins (SCAPs). SCAP, in turn, can bind reversibly with another
endoplasmic reticulum-resident membrane protein, INSIG. SCAPs bind to SREBP-2 in the
endoplasmic reticulum where a regulatory domain within SCAP responds to the level of
oxysterols present in the cell. When the intracellular cholesterol and oxysterols concentrations
decrease, the SREBP/SCAP complex moves to Golgi apparatus, leaving INSIG. Two proteases
localized in Golgi, site-1 and -2 proteases (S1P and S2P) cleave SREBP-2 to release the tran‐
scription activation domain of SREBP-2. SREBP-2 preferentially activates transcription of
target genes of LDL receptor [41]. When oxysterol levels are high, the SCAP/SREBP complex
remains in the endoplasmic reticulum, preventing cleaved SREBP-2 from promoting gene
expression. In addition to the up-regulation of LDLR transcription, nuclear SREBP-2 increases
the transcription of PCSK9, a sterol-responsive protein that accelerates LDLR turnover in the
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liver, thereby limiting lipoprotein uptake. As high concentrations of cellular cholesterol
suppress SREBP-2 cleavage and release from endoplasmic reticulum, PCSK9 transcription is
reduced, which subsequently increases LDLR levels, helping to maintain cholesterol homeo‐
stasis [43].
7.2. Regulation of cholesterol biosynthesis
SREBPs directly activate the expression of more than 30 genes dedicated to the synthesis and
uptake of cholesterol, fatty acids, triacylglycerols, and phospholipids, as well as the reduced
nicotinamide adenine dinucleotide phosphate (NADPH) cofactor required to synthesize these
molecules. SREBP-2–responsive genes in the cholesterol biosynthetic pathway include those
for the enzymes HMG-CoA synthase, HMG-CoA reductase, farnesyl diphosphate synthase,
and squalene synthase. SREBP-1c and SREBP-2 activate three genes required to generate
NADPH, which is consumed at multiple stages in these lipid biosynthetic pathways [41]. High
cholesterol/oxysterol levels acting on SCAP ultimately stop the maturation of SREBPs,
resulting in the down regulation of key enzymes such as HMG-CoA reductase, thus, reducing
the amount of cholesterol produced by the liver. To compensate the decreased cholesterol
synthesis a homeostatic response in which cells increase the density of LDL receptors on their
surfaces. This increases the clearance rate of LDL particles from the plasma and reduces plasma
LDL cholesterol and its related health risks. The decrease in cholesterol synthesis also promotes
an increase of HDL, thus, clearing even more cholesterol from the plasma.
Elevated levels of cellular cholesterol are accompanied by the increased production of
oxysterols, which are specificligands of LXRs, allowing LXRs to function as cholesterol sensors
[44]. LXRs respond to elevated cholesterol levels via transactivationof genes involved in sterol
transport (ABCA1, ABCG1, ABCG5,and ABCG8), cholesterol efflux and HDL metabolism
(ABCA1, APOE, CETP, and PLTP), and sterol catabolism(CYP7A1). Additionally, LXRs also
play a central role in regulatingcellular lipid content through activation of SREBP-1c, whichis
the master regulator of de novo lipogenesis [40]. In response to activation, LXRs act in a
coordinated fashion to maintain cholesterol homeostasis by directing the tissue-specific
expression of genes involved in sterol transport and metabolism [45]. A principal function of
LXR in macrophages is to promote cholesterol removal from the cell through the induction of
ABCA1, ABCG1, and apolipoprotein E. LXR also induces genes involvedin lipoprotein
metabolism, including LPL, CETP, and PLTP [45].
7.3. Regulation of cholesterol absorption and secretion
At the intestine, cholesterol is absorbed into enterocytes by a mechanism involving Niemann
Pick C1-like protein 1 (NPC1L1) [46]. The NPC1L1 protein is abundant on intestinal brush
border membranes. It functions as a sterol transporter to mediate intestinal cholesterol
absorption and counterbalances hepatobiliary cholesterol excretion [46]. NPC1L1, is not under
control of a nuclear receptor LXR [47]. In the enterocyte, cholesterol is readily esterified by the
action of acyl-CoA:cholesterol acyltransferase 2 (ACAT2) and released into lymph in associa‐
tion with chylomicrons. The ATP-binding cassette (ABC) transporter protein ABCA1 andthe
ABC half-transporters, ABCG5 and ABCG8, are LXR target genesin the intestine and partici‐
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pate in cholesterol absorption. ABCA1 and ABCG5/8 counteract cholesterol absorption via
effluxof cholesterol from the enterocyte into the gut lumen. LXR agonists exerttheir effect on
cholesterol absorption through upregulationof ABCG5 and ABCG8, which is necessary for the
majority of sterols secreted into bile [40, 48].
7.4. Regulation of cholesterol transport
The hepatic nuclear receptor, PPARα, exert control over many aspects of reversecholesterol
transport. Hepatic synthesisof apoA-I and apoA-II, the two major apolipoproteins in discoi‐
dalHDL ( HDL2), is regulated via PPARα activation and transcriptional regulation ofRORα
(NR1F1), a widely expressed nuclear receptor that is activatedby cholesterol or cholesterol
sulfate ligands [49]. ABCA1, which helps in reverse transport from peripheral tissues, is
PPARγ/LXR-regulated cholesterol/phospholipid transporter [50]. PLTP is activatedby both
LXR and FXR whereas CETP is transactivated by LXR [40,51].
7.5. Excretion of cholesterol
Bile acids are synthesized in hepatocytes and this production is tightly controlled by the
nuclear receptor transcription factors, LXR-α and LXR-β. Activation of LXRs by specific
oxysterol derivatives leads to the regulation of bile acid synthesis by stimulating cholesterol
7α-hydroxylase (CYP7A1) transcription to convertcholesterol to bile acids. FXR, a bile acid
receptor, plays a central role of lipid metabolism in liver cells. FXR may play the major roles
in bileacid metabolism, reverse cholesterol transport, and protecthepatocytes against choles‐
tasis by feedback inhibition ofbile acid synthesis by CYP7A1; stimulation of bile acid efflu‐
xfrom hepatocytes by bile salt export pump; inhibition of bile acid uptakeinto hepatocytes by
Na+-taurocholate co-transporting polypeptide; and regulation of reverse cholesteroltransport
by inducing ApoCII and PLTP [40, 52].
8. Cholesterol-lowering drugs
Mainly cholesterol lowering drugs have been developed and used clinically, which includes
1) HMG-CoA reductase inhibitors, e.g., atorvastatin, fluvastatin, lovastatin, pravastatin,
rosuvastatin and simvastatin, 2) bile acid sequestrants — colesevelam, cholestyramine and
colestipol — and nicotinic acid (niacin), and 3) cholesterol absorption inhibitor - ezetimibe.
Other available drugs are gemfibrozil, fenofibrate and clofibrate which are fibric acid deriva‐
tives primarily used for lowering high triglyceride levels
8.1. Statins – Benefits versus side effects
Statins or inhibitors of 3-hydroxy-3-methylglutaryl–coenzyme A (HMG-CoA) reductase are
widely used to reduce the risk of cardiovascular events and death. Statins includes lovastatin,
which is a fungal metabolite, and many synthetic derivatives, pravastatin, atorvastatin and
simvastatin etc. Statins target predominantly hepatocytes and inhibit HMG-CoA reductase,
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the enzyme that converts HMG-CoA into mevalonic acid, a cholesterol precursor. Statins alter
the conformation of the enzyme when they bind to its active site. This prevents HMG-CoA
reductase from attaining a functional structure. The change in conformation at the active site
makes these drugs very effective and specific [53]. Binding of statins to HMG-CoA reductase
is reversible, and their affinity for the enzyme is in the nanomolar range, as compared to the
natural substrate, which has micromolar affinity [54]. The inhibition of HMG-CoA reductase
determines the reduction of intracellular cholesterol, inducing the activation of a protease
which slices SREBPs from the endoplasmic reticulum. SREBPs are translocated into nucleus,
where they increase the gene expression for LDL receptor. The reduction of cholesterol in
hepatocytes leads to the increase of hepatic LDL receptors that leads to the reduction of
circulating LDL and of its precursors (intermediate density - IDL and very low density- VLDL
lipoproteins). All statins reduce LDL cholesterol non-linearly, dose-dependent, and after
administration of a single daily dose [53]. Statins inhibit hepatic synthesis of apolipoprotein
B-100, determining a reduction of the synthesis, secretion of triacylglycerols-rich lipoproteins,
and an increase of receptors for apolipoproteins B/E. Statins have a modest effect on HDL
increase, and no influence on lipoprotein(s) concentration. Statins can also prevent LDL
oxidation by preserving the activity of the endogenous antioxidant system, like superoxide
dismutase [53].
In general, the currently used statins are well tolerated and have a good safety profile [55].
Statins acting as inhibitor of HMG-CoA reductase, inhibits all the pathway in which mevalo‐
nate is a precursor such as synthesis of nonsteroid isoprenoids such as farnesylpyrophosphate
(FPP), geranylgeranylpyrophosphate (GGPP), dolichol and side chain of coenzyme Q which
play an essential role in cellular physiology. Coenzyme Q is a component of mitochondrial
respiratory chain and a lipid-soluble antioxidant. Farnesyl- and geranylgeranyl groups are
needed for protein isoprenylation and formation of small GTP-binding proteins including Ras,
Rho and Rab, which are involved in signal transduction pathways. Inhibition of isoprenoid
synthesis by statins decreases the activity of these proteins and modifies the respective
signalling pathways; the mechanism responsible for cholesterol-independent pleiotropic
effects of statins. The best recognized and most commonly reported adverse effect of statins
are muscle adverse effect with muscle pain, fatigue and weakness as well as rhabdomyolysis.
Rhabdomyolysis is the most severe form of statin induced myopathy, characterized by marked
increase in CK activity, myoglobinemia, myoglobinuria, and myoglobin induced acute renal
failure. These symptoms arising on statins are shown to be reversed with discontinuation.
Coenzyme Q10 deficiency produces mitochondrial encephalomyopathy, resulting in fatigue,
muscle symptoms, and cognitive problems. Gastrointestinal and neurological symptoms,
psychiatric symptoms, sleep problems, glucose elevations, and a range of other symptoms are
also reported on statins [56].
8.2. Ezetimibe – Benefits and side effects
Ezetimibe is the first of a new class of highly selective cholesterol absorption inhibitors. It does
not inhibit cholesterol synthesis in the liver or increase bile acid excretion. It belongs to a class
of lipid-lowering compounds that selectively inhibits the intestinal absorption of cholesterol
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and sterols. Ezetimibe's pharmacological effect is complementary to that of the statins [57].
Mechanism of action of ezetimibe involves inhibiting the absorption of cholesterol in the small
intestine. Through a mechanism that is not yet fully elucidated, ezetimibe appears to block a
protein transporter called Niemann-Pick C1-like 1 protein (NPC1L1) that is located at the apical
membrane of the small intestine enterocytes [58]. Unlike other cholesterol-lowering agents,
ezetimibe localizes and appears to act at the brush border of the small intestine and inhibits
the absorption of dietary and biliary cholesterol in the small intestine, leading to a decrease in
the delivery of intestinal cholesterol to the liver. This leads to a reduction of hepatic cholesterol
stores and an increase in clearance of cholesterol from the blood. Ezetimibe has been demon‐
strated to have no significant effect on the plasma concentrations of the fat-soluble vitamins
A, D, and E [57]. No published reports could be identified that assessed the potential impact
of ezetimibe therapy on other traditional CVD risk factors, including blood pressure and
obesity. Recent reports have raised concerns about an association between ezetimibe and an
increased incidence of cancer [58]. Ezetimibe may rarely cause hepatotoxicity, severe choles‐
tatic hepatitis, or acute autoimmune hepatitis [59].
Ezetimibe is proved to be more effective in combination with statin drugs in lowering LDL-c
than monotherapy. Ezetimibe has an additive and at times synergistic effect on the reduction
of LDL-C and total cholesterol (TC) concentrations when combined with statin therapy.
Ezetimibe has not been associated with increased rates of myopathy or rhabdomyolysis,
whether used alone or in combination with statins, although there have been some case reports
of myopathy attributed to this agent. Moreover, ezetimibe has been associated with mild
elevations of liver transaminases, mainly in combination with a statin. Other side effects are
extremely rare. It should be noted, however, there are no long-term safety data or outcome
studies for ezetimibe yet [60].
8.3. Niacin (Nicotinic acid)
Niacin is the most potent HDL increasing drug currently available and it also can efficaciously
lowers triglycerides and LDL cholesterol. It is the only lipid-lowering drug that considerably
lowers lipoprotein(a). Beneficial effect of niacin to reduce triglycerides and apolipoprotein-B
containing lipoproteins (e.g., VLDL and LDL) are mainly through: a) decreasing fatty acid
mobilization from adipose tissue triglyceride stores, and b) inhibiting hepatocyte diacylgly‐
cerol acyltransferase and triglyceride synthesis leading to increased intracellular apo B
degradation and subsequent decreased secretion of VLDL and LDL particles. Niacin raises
HDL by decreasing the fractional catabolic rate of HDL-apoAI without affecting the synthetic
rates. Additionally, niacin selectively increases the plasma levels of lipoprotein-AI (HDL
subfraction without apoAII), a cardioprotective subfraction of HDL in patients with low HDL.
Recent studies indicate that niacin selectively inhibits the uptake/removal of HDL-apoAI (but
not HDL-cholesterol ester) by hepatocytes, thereby increasing the capacity of retained HDL-
apoAI to augment cholesterol efflux through reverse cholesterol transport pathway [61].
Niacin treatment is associated with a number of side effects, including headache, itching and
gastrointestinal disturbances, but these are generally mild. The most severe of the side effects
is flushing, and this is sufficiently severe to negatively affect compliance [62].
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8.4. Bile acid sequestrant
Bile acid sequestrant or bile binding anion (Chloride) exchange resins that is effective in
reducing total cholesterol and LDL cholesterol levels. The primary and direct action of the bile
acid sequestrants is to bind to bile acids in the gut and thus interrupt the enterohepatic
recirculation of bile acids [63]. Three key enzyme are affected by bile acid sequestrant, which
are phosphatidic acid phosphatase, cholesterol 7-alpha-hydroxylase and HMG-CoA reduc‐
tase. Activation of phosphatidic acid phosphatase promotes hepatic triglyceride synthesis,
induces secretion of triglyceride-rich VLDL particles and consequently increases plasma
triglyceride levels. The activation of hepatic cholesterol 7-alpha-hydroxylase promotes the
conversion of intracellular cholesterol to bile acids. The decrease in intracellular cholesterol
stores, in turn, increases LDL receptor expression on hepatocyte membranes and consequently,
increases receptor-mediated fractional catabolism of LDL or LDL uptake by liver cells.
Reduction of intracellular cholesterol may also increase the synthesis of cholesterol through
activation of HMG-CoA reductase. The potential loss of the bile acid sequestrant's cholesterol-
lowering efficacy can be overcome by adding HMG-CoA reductase inhibitor (statins). Finally,
bile acid sequestrants promote apoprotein AI synthesis and tend to raise high-HDL cholesterol
levels, primarily by increasing plasma HDL-2 concentrations. Three drugs in this class are
synthetic cholestyramine, colestipol, colesevelam. The side effect profile of the bile acid
sequestrants is tolerable, with most complaints related to effects on the gastrointestinal tract
and the bulkiness of resins [64].
8.5. Fibrates
Fibrates are primarily effective for the treatment of hypertriglyceridemia or mixed hyper‐
lipidemia  by  stimulating  the  peroxisomal  β-oxidation  pathway.  Their  main  action  is  to
lower plasma triglyceride levels,  but they also reduce total  and LDL cholesterol concen‐
trations and induce a moderate increase in HDL cholesterol.  Fibrates act  by stimulating
the  activity  of  peroxisome  proliferator-activated  receptor  (PPAR)-α,  a  member  of  the
PPAR  subfamily  of  nuclear  receptors  [65].  It  controls  the  transcription  of  regulatory
genes of fatty acids and cholesterol metabolism. It inhibits the synthesis and secretion of
triglycerides by the liver and a stimulation of the degradation of triglyceride-rich lipopro‐
teins.  This  increased clearance  of  triglycerides  results  from a  stimulation  of  the  expres‐
sion  of  lipoprotein  lipase  and  a  decreased  expression  and  concentration  of
apolipoprotein-CIII, an inhibitor of lipoprotein lipase activity. PPAR-α activation modifies
the expression of several key genes controlling HDL cholesterol metabolism and reverse
transport of cholesterol [65]. Several fibrate drugs such as ciprofibrate, bezafibrate, fenofi‐
brate, and gemfibrozil has revolutionized lipid-lowering but research has shown the pro‐
longed  use  of  some  of  these  drugs  like  clofibrate  and  ciprofibrate  causes  peroxisome
proliferation leading to hepatomegaly and tumor formation in the liver of rodents [66].
A recent report demonstrated that between the periods 1988-1994 and 1999-2002, mean total
cholesterol and mean LDL cholesterol declined in American adults. Coincidently, during this
time there also was an increase in the percentage of adults receiving lipid-lowering medica‐
tions. However, among adults not receiving lipid-lowering medications, trends in lipids were
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similar to those reported for adults overall. Among obese adults, mean total cholesterol, non–
HDL cholesterol, LDL cholesterol, and geometric mean triglycerides declined between 1988
and 2010[67]. These data suggest that in addition to the increased use of lipid-lowering
medications, something else must have been involved in the overall reduction of blood total
cholesterol and LDL cholesterol. Although those factors, the application of natural lipid-
lowering products plays a critical role and is thus described below.
9. Cholesterol-lowering natural products
9.1. Plant sterols/ stanols
Plant sterols/ stanols, naturally occurring in foods of plant origin, perform similar biological
functions to cholesterol, and contain a similar chemical structure. They differ from cholesterol
only in the presence of either an extra methyl or ethyl group. Absorption efficiency for plant
sterols in humans is less (2-5%) than that of cholesterol (60%). The most common forms are
unsaturated plant sterols β-sitosterol, campesterol, and stigmasterol and the saturated
sitostanol and campestanol [68]. Plant sterols reduce the absorption of both dietary and biliary
cholesterol from the intestinal tract by 30%–50% [69]. The exact mechanism is yet fully
elucidated while it is generally assumed that the presence of increased quantities of plant
sterols in the gut lowers the micellar solubility of cholesterol, therefore lowering the amount
of cholesterol available for absorption [69]. Intake of phytosterol and stanols at an average of
2 g/day has been shown to lower low density lipoprotein cholesterol (LDL-C) by 10-15%. The
effect appeared to be peaked at intakes of 2 g/d, with little additional benefit being achieved
at intakes higher than 2.5 g/d. The recommended daily intake of phytosterols is 2 g/d in humans
[70]. Plant sterols and their derivatives reduce plasma cholesterol levels independently from
the mRNA expression of ABCG5 and ABCG8 transporters [71]. Food products such as
margarine, milk, yoghurt, and cereal products enriched with plant sterols/stanols are promot‐
ed as functional foods to help lower serum cholesterol levels. Human and animal studies have
shown that plant sterol and stanol esters are non-toxic [72]. There have been concerns raised
over the reduced absorption of some fat soluble vitamins from the use of plant sterols. For
example, plant sterols and stanols have been shown to reduce β-carotene, α-carotene, and
vitamin E levels by around 25%, 10%, and 8%, respectively [72]. Used alone in the diet, or as
an adjuvant to drug therapy, or in combination with other functional food components, plant
sterols/stanols-enriched products are generally effective at reducing serum total and LDL-C
[72], and thus the most popular natural ingredient in cholesterol-lowering product market.
9.2. Soy products
Soy foods have been consumed for centuries in Asian countries. Consumption of soy foods
contribute to lower incidences of coronary heart diseases, atherosclerosis, type 2 diabetes, and
decreased risk of certain types of carcinogenesis such as breast and prostate cancers [73].
Animal and human studies have also shown that consumption of soy protein or associated
isoflavones has beneficial impacts such as lowering liver or blood triglyceride, total and LDL
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cholesterol levels, increasing HDL cholesterol and the ratio of HDL/LDL cholesterol [73, 74].
Soy protein regulates SREBP-1 expression by modulating serum insulin concentration, thus
preventing the development of fatty liver [75]. Isoflavones are major soy phytoestrogens
present in soy foods and Genistin, daidzin, and glycitein are the main soy isoflavones (Xiao
2008). Soy and soy bioactive components are well-tolerated and the adverse effects reported
are gastrointestinal symptoms (e.g., diarrhea), followed by menstrual complaints (e.g.,
prolonged periods, amenorrhea) headache, dizziness, and musculoskeletal complaints [76].
9.3. Dietary fibre
Dietary fibre is one of the most studied dietary components associated with cardiovascular
benefits. It is a complex of non-digestible carbohydrates and lignin that are intrinsic and intact
in plants and are resistant to digestion and absorption in the small intestine. Dietary fibre can
modulate body weight and promotes beneficial physiological effects such as laxation, reduc‐
tion in blood cholesterol and postprandial blood glucose [77]. Traditionally, dietary fibre has
been classified on the basis of its solubility in water (soluble or insoluble). Foods rich in fibre
need to be chewed longer, leading to an increase in the time needed to eat and the feeling of
satiety. Fibres which make up viscous solutions also delay the passage of food from the
stomach to duodenum and contribute to an increase in satiety and a decrease in energy
consumption [78]. In the intestine, the incorporation of fibre in food may complicate the
interaction between digestive enzymes and their substrates, thus slowing down the absorption
of nutrients[77]. The hypocholesterolemic action of fibre is partly mediated by a lower
absorption of intestinal bile acid because the interruption of the enterohepatic bile acid
circulation, thus increasing faecal bile acid loss, and its de novo synthesis in liver. The
physicochemical properties of soluble fibre result in important modifications in volume, bulk
and viscosity in the intestinal lumen, which will alter metabolic pathways of hepatic cholesterol
and lipoprotein metabolism, also resulting in lowering of plasma LDL cholesterol [79]. Dietary
fibre increases the enzymatic activity of cholesterol-7-α-hydroxylase, contributing to a higher
depletion of hepatic cholesterol but increased endogenous cholesterol synthesis. However,
there is an increase in the number of LDL receptors and in the recruitment of the esterified
cholesterol from the circulating LDL particles. Several types of soluble dietary fibre such as
pectin, glucomannan, psyllium can decrease plasma total cholesterol and LDL cholesterol.
Epidemiological evidences showed a stronger association of cardiovascular protection with
soluble fibre than insoluble fibre. Insoluble fibre such as that from wheat or cellulose has not
been reported to have any significant effect on blood cholesterol [78]. Consumption of too
much high fibre foods that have not been cooked can cause side effects of abdominal bloating
and gas.
9.4. Flaxseed lignans
Flax seed is the richest source of natural lignans, with secoisolariciresinol diglucoside (SDG)
being the principal lignan compound. Flaxseed or flaxseed meal have cardioprotective
properties and can suppress atherosclerosis by virtue of its antioxidant properties due to the
presence of flaxseed lignans. Lignan reduces serum triglycerides and LDL and raises HDL
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cholesterol. In addition, flaxseed oil possesses anti-inflammatory properties and reduces
platelet aggregation as well [80]. Flaxseed lignans along with soy isoflavones are phytoestro‐
gens commonly consumed in the human diet.
9.5. Polyunsaturated fatty acids and omega-3 fatty acids
An  old  assumption  regarding  fatty  acids  and  their  effects  on  atherosclerosis  was  that
monounsaturated fatty acids were neutral, saturated fatty acids were bad, and polyunsa‐
turated fatty  acids  were  good.  However,  a  study conducted by Scott  Grundy and Fred
Mattson  in  1985  turned  the  “world  of  monounsaturated  fatty  acids”  around[81].  They
demonstrated that diets rich in saturated fatty acids caused a high LDL cholesterol/HDL
cholesterol  ratio,  and that  substitution of  monounsaturated fatty acid for  saturated fatty
acids  reduced  LDL  cholesterol  but  did  not  reduce  HDL  cholesterol.  Consequently  the
LDL cholesterol/HDL cholesterol ratio was the lowest with monounsaturated fatty acids,
given that polyunsaturated fatty acids reduced HDL cholesterol as well as LDL cholester‐
ol.  A similar  phenomenon was observed in a  5-year  study in male  African green mon‐
keys[82].  In  the  monkey  studies,  average  HDL  cholesterol  was  50  mg/dl  in  the
polyunsaturated  fatty  acids  group  versus  86  and  81  mg/dl  in  the  saturated  fatty  acids
and monounsaturated fatty  acids  groups,  respectively.  Average  plasma LDL cholesterol
concentrations  in  the  polyunsaturated  fatty  acids  and  monounsaturated  fatty  acids-fed
monkeys were 157 and 167 mg/dl,  respectively (no significant difference between them)
versus 257 mg/dl in the saturated fatty acids-fed animals.
The influences of dietary fatty acids on blood cholesterol profiles are also related to diet
composition[83]. It is well accepted that the consumption of saturated fatty acids increases
LDL cholesterol, whereas carbohydrates, monounsaturated fatty acids and polyunsaturated
fatty acids do not. The effect of fatty acids on blood lipid profiles also depends on heath
conditions. Among individuals who are insulin resistant, a low-fat, high-carbohydrate diet
typically has an adverse effect on lipid profiles. In addition to lowering HDL cholesterol, it
also increases triacylglycerols and LDL cholesterol. Consequently, a moderate fat diet in which
unsaturated fatty acids replace saturated fatty acids and carbohydrates are not augmented is
advised to lower LDL cholesterol[83].
Fish oil (marine n-3 fatty acids, eicosapentaenoic acid, and docosahexaenoic acid), whether
from dietary sources or fish oil supplements, exhibit cardioprotective effects and reduce
mortality due to cardiovascular diseases. Fish oil provides cell membrane stabilization, anti-
inflammatory, antiatherogenic effects and suppression of cardiac arrhythmias[84]. Omega-3
fatty acids lower moderately the blood pressure through primarily the improvement of
vascular endothelial cell function whilst a multitude of mechanisms may be involved85.
Polyunsaturated fatty acids lower triacylglycerols, which has also been important in cardio‐
protection and the management of insulin resistance and diabetes. The effect of omega-3 fatty
acids on blood cholesterol is inconsistent effect. In general, omega-3 fatty acids do not offer a
benefit of directly lowering blood cholesterol. Instead, in some studies fish oil has been found
to cause a small rise in LDL-cholesterol; however a change in the LDL particle size from the
smaller more atherogenic form to the larger less damaging particle size have been noted85.
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Health Canada has recently reconsidered the classification of food products with disease risk
reduction claims or therapeutic claims in light of clarified principles for the classification of
foods at the Food-Natural Health Product interface (http://www.hc-sc.gc.ca/fn-an/label-
etiquet/claims-reclam/assess-evalu/sat-mono-poly-fat-gras-eng.php). Health Canada has
concluded that the results of the updated literature review are consistent with the 2002 report
provided by the Institute of Medicine (IOM), which forms the basis of the US and Canada
dietary guidance, on the replacement of saturated fat with unsaturated fat for blood cholesterol
lowering. In other words, scientific evidence exists in support of the therapeutic claim linking
the replacement of saturated fat with unsaturated fat to a reduction of blood cholesterol. It is
stated that the claim is relevant and generally applicable to the Canadian population as a high
proportion of the Canadian population is hyperlipidemic. It is allowed now by the Health
Canada's to put therapeutic claim statements such as “Replacing saturated fats with polyun‐
saturated and monounsaturated fats (from vegetable oils) helps lower/reduce cholesterol” in
vegetable oils and foods containing vegetable oils when specific conditions for the food
carrying the claim are met.
9.6. Olive oil
Olive oil can reduce LDL and raise high-density lipoprotein cholesterol and decrease lipid
damage due to oxidative stress. In addition, olive oil reduces inflammatory and thrombogenic
status, endothelial dysfunction, and blood pressure[86].
9.7. Green tea products
Tea catechin-especially (-)-epigallocatechin-3-gallate-inhibits the expression of soluble
adhesion molecules including vascular adhesion molecule-1 and intercellular adhesion
molecule-1, endothelial cell inflammatory markers, decreased oxidized LDL, and prevents the
development of atherosclerosis and[87].
Certainly, there are more natural products available, for instance a number of antioxidants and
phenolic compounds, to lower blood cholesterol levels. However, the big challenges that the
natural products have been facing in the past years lie in their relatively lower efficacies as
compared with the cholesterol-lowering drugs. The apparent advantages of natural products
are their better safety profiles. In order to promote the market share of cholesterol-lowering
natural products in competing with the drugs, it is critical to develop new products that can
offer better efficacies than the current natural products, without losing safety or introducing
increased toxic or severe side effects. Considering that the majority of the current natural
products fall into the same category of cholesterol absorption inhibitor, the future direction of
research and development of cholesterol-lowering products, novel distinct pathways or
targets should be focused. Herewith, we will provide some brief thoughts on new approaches
that we believe worth to tackle into, with a hope that the new mind in the research and
development direction and focus would help to discover and develop novel natural products
with significantly improved cholesterol-lowering efficacy working through distinct mecha‐
nisms than the currently available natural products, without apparent side effects.
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10. New perspectives on the development of natural cholesterol-lowering
products
Cardiovascular friendly natural products are those nutritional supplements, which can
provide potential health benefits in cardiovascular diseases (CVD). Experimental, epidemio‐
logical and clinical data indicates that dietary nutrients and supplements have profound
cardioprotective effects in the primary as well as secondary prevention of coronary heart
disease [88]. Except for the aforementioned several cholesterol-lowering natural products, the
plant alkaloid berberine has recently been introduced to the filed of lipid-lowering products.
Berberine has shown a moderate or comparable cholesterol- and triacylglycerol-lowering
effect in humans [89]. More importantly, recent studies have demonstrated that berberine
combined with plant stanols improves cholesterol-lowering efficacy through a synergistic
action on cholesterol absorption and reducing plasma triacylglycerols in animals [90], [91],
with the efficacies are comparable or even better cholesterol-lowering drugs, statins. The
product has been patent-protected and at the preclinical stage. Clinical trials are warranted
before moving this potentially highly effective natural product to the lipid-lowering market.
10.1. Current status in the development of cholesterol-lowering products
An initial approach to control the modifiable risk factors of hyperlipidemia relies on the
changes of diet, lifestyle, and other factors such as smoking. When all these fail, pharmaceutical
intervention is necessary. Many of the current available drugs are those either inhibit choles‐
terol synthesis, or increase synthesis of bile acids and excretion. The majority of the current
research focuses on lowering the “bad” LDL cholesterol, with less attention on increasing
“good” HDL cholesterol. A treatment with a combination that can lower LDL cholesterol and
increase HDL cholesterol would certainly provide more benefits than single approach for the
treatment of hyperlipidemia, atherosclerosis and cardiovascular disease.
10.1.1. Lowering LDL cholesterol
Statins drugs, which are currently widely prescribed, lower LDL cholesterol primarily via
inhibiting cholesterol biosynthesis and a secondary effect of increase LDL receptor and LDL
clearance. However this family of drugs has shown several undesirable side-effects. Niacin,
can also lower LDL cholesterol but not efficiently as statin but it is only one drug proved to
increase HDL cholesterol with very less side effects. Therefore, a combination of niacin and
statins might be superior to these drugs alone for lowering lipid levels. The scientific evidence
of long-term safety and tolerability of these combination therapies are key determinants for
good compliance and cardiovascular benefits.
Proprotein convertase subtilisin kexin-9 (PCSK9) is a sterol-responsive protein that accelerates
LDLR turnover in the liver. When PCSK9 transcription is reduced, there will be subsequently
increases LDLR levels helping to maintain cholesterol homeostasis. The transcription of PCSK9
is increased by SREBP-2, which also regulate the transcription of many other genes. Therefore,
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a pharmacologically specific inhibitor of PCSK9 will have atherogenic effect by increasing
LDLR levels without affecting other genes regulated by SREBP-2.
10.1.2. Increasing HDL levels
Low HDL-cholesterol (HDL-C) is a strong and independent cardiovascular risk marker. Niacin
is the only drug proved to increase HDLC but associated with flushing as a side-effect. Niacin-
induced flushing involves both PGD2 from mast cells and serotonin from platelets. The
possibility of administering or formulating niacin together with flavonoid luteolin was
recently shown to inhibit niacin flush in rats. Further investigation on inhibitors on side-effect
can warrant an effective medicine for CVD[92]. Aleglitazar, a dual PPARα/γ agonist, proven
has beneficial effects on both lipid and glucose parameters [93]. Activation of PPARα may
increase ApoA1, apolipoprotein of HDL and increased the synthesis of LPL which hydrolyzes
VLDL, IDL and LDL. PPARα agonist, with good safety profile, may have a therapeutic role in
modifying cardiovascular risk factors.
10.1.3. CETP inhibition
Besides established strategies to increase HDL-C, e.g. with nicotinic acid, CETP (Cholesteryl
ester transfer protein)-inhibition is a promising new therapeutic option. The failure of
torcetrapib, the first CETP-inhibitor, seems to be attributed to "off-target" effects. Treatment
with the newer CETP-inhibitors dalcetrapib and anacetrapib has been shown to be efficacious
and safe - but their usefulness in clinical practice remains to be determined in ongoing clinical
trials [94].
10.1.4. Inhibition of cannabinoid receptors
G protein-coupled cannabinoid receptor, CB-1 of the endocannabinoid system, plays a crucial
role in regulating feeding pattern, lipid metabolism, and energy homeostasis. CB-1 receptors
are located in the central nervous system and peripheral tissues including adipocytes,
pancreas, gut, liver, and muscle. Rimonabant, a selective CB-1 antagonist drug to be developed
for weight loss via increasing energy expenditure actually also increases HDL-cholesterol and
triglycerides.However, the clinical efficacy and safety of these new antiobesity compounds are
yet to be determined. Additional cannabinoid receptor blockers have been developed and are
in testing [95].
10.1.5. Nuclear receptor modifiers
Identification of nuclear receptor LXR and FXR as regulatorof genes in bile acid and cho‐
lesterol metabolism has providedpotential  new targets for screening cholesterol-lowering
drugsby manipulating  bile  acid  synthesis,  transport,  and absorption.  Therapies  targeted
to LXR and FXR would be ideal for drug developmentbecause nuclear receptors are acti‐
vated  by  natural  and  syntheticligands,  which  could  be  identified  by  high-throughput
screening [96].
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10.1.6. Acyl-coenzyme A: Cholesterol acyltransferas (ACAT) inhibitors
ACAT 1 and ACAT2 play an important role in cellular cholesterol esterification and thus
modulate intestinal cholesterol absorption and hepatic lipoprotein secretion. ACAT2 is
proposed to play a central role in cholesterol absorption from the intestine. ACAT1, on the
other hand is widely distributed in tissues, and plays a pivotal role in cholesterol metabolism
in macrophages and steroidogenic tissues. It is anticipated that inhibitors of ACAT2 activity
could be developed that would decrease cholesterol absorption, whereas specific ACAT1
inhibitors could be used to reduce foam cell formation and prevent atherosclerosis. However,
the results of studies have indicated that ACAT1 inhibition is not a good strategy and, in fact,
could have detrimental consequence [97]. In contrast, mice lacking ACAT2 exhibited attractive
metabolic findings. These include a restricted capacity to absorb cholesterol and protection
against diet-induced hypercholesterolemia and gallstone formation [98, 99]. Further, ACAT2
inhibitor reduces cholesterol esters in apolipoprotein B-containing lipoproteins and protects
from atherosclerosis in murine models of the disease [100]. A fundamental question remains:
would ACAT2 specific inhibition in humans, either pharmacologically or with anti-sense
oligonucleotides, prevent or reduce atherosclerosis? “The sole test of the validity of an idea is
experiment.” Until a potent and specific inhibitor of ACAT2 is tested in humans, the hypothesis
remains uncertain [101].
10.2. Future perspectives of cholesterol-lowering products and their potential impact on
CVD
10.2.1. Identification of new molecular targets
Target identification is an essential first step in drug development. Although cholesterol
metabolism has been studied for decades and relatively well understood, the specific molec‐
ular targets that can be used for drug discovery and development are far from well-known. It
is believe that with the development and use of modern molecular technology and techniques
in nutritional and physiological research, more targets will be indentified and used for future
drug development.
10.2.2. Application of gene silencing technology
Apart from the identification of new targets, several new approaches have been introduced or
shown great potential for the development of new cholesterol-lowering products. Of them is
gene-silencing technology. One technology that has generated a lot of excitement is RNA
interference (RNAi) [102]. For example, clinical trials have been launched using RNA inter‐
ference approaches to reduce PCSK9 expression or specific antibodies targeting and inhibiting
PCSK9 interaction with the LDL receptor. They constitute very promising approaches to
reducing cholesterol levels and coronary heart disease. Understanding of PCSK9 and its
potential as a therapeutic target through which to reduce LDL cholesterol for prevention and
treatment of coronary heart disease has been of great interest recently [103]. The administration
of chemically modified small interference RNAs (siRNAs) results in silencing of a target
mRNA, such as apolipoprotein B (apoB) mRNA in liver and jejunum and decreasing plasma
A New Perspective on the Development of Cholesterol-Lowering Products
http://dx.doi.org/10.5772/54729
203
levels of apoB protein. ApoB is a molecule involved in the metabolism of cholesterol; the
concentrations of this protein in human blood samples correlate with those of cholesterol.
Higher levels of both compounds are associated with an increased risk of coronary heart
disease. Intravenous injections of the siRNA-cholesterol conjugates in mice resulted in a
lowering of the levels of blood cholesterol comparable to that in mice in which the apoB gene
had been deleted. These results demonstrate that siRNA can be delivered systemically to target
the liver and suggest that RNAi has the potential to become a new therapeutic for the treatment
of metabolic diseases [102].
10.2.3. Development of target-specific inhibitors or enhancers
For those molecular targets that have several different isoforms, the biggest challenge in
the drug development is the specificity. A good example is ACAT inhibitors. To date, it
has been demonstrated that  there are two sioforms,  ACAT1 and ACAT2.  ACAT1 is  ex‐
pressed  universally  while  ACAT2  is  expressed  mainly  in  the  liver  and  small  intestine.
Both  isoforms  can  esterify  cholesterol  and  other  sterols.  However,  ACAT1  primarily
works on the esterification of plant sterols and other sterol products, while ACAT2 main‐
ly converts cholesterol to its esters. Due to their different distribution and activities in the
body, a universal inhibitor of both enzymes has been shown to be detrimental and recent
humans trials  are disappointing [104,  105].  The study of  Bell  et  al.  in 2006 breathes life
back  into  the  idea  of  ACAT2-specific  inhibition  [106].  In  atherosclerosis-prone  mice,
ACAT2  was  specifically  ihibhied  in  the  liver  with  antisense  oligonucleotides.  Biweekly
intraperitoneal  injections,  which  reduced  ACAT2  expression  by  a  remarkable  80%,  de‐
creased diet-induced hypercholesterolemia and sharply reduced cholesterol  ester deposi‐
tion  in  the  aorta.  The  specific  inhibition  can  be  achieved  from  the  antisense  gene
technology or  small  molecules  that  inhibit  only ACAT2.  There  is  no mature product  in
this category and lots more work needs to be done.
It has been demonstrated by numerous studies that inhibition of cholesterol absorption is
associated  with  much  less  side-effects  than  other  approaches.  It  remains  challenge  but
highly promising that a potent inhibitor of cholesterol absorption would sufficiently low‐
er  blood  cholesterol  or  keep  blood  cholesterol  levels  within  the  recommended  healthy
range. To achieve this goal,  other approaches have to be take in addition to the specific
inhibitor  of  cholesterol  absorption,  such  as  a  combination  of  two  or  more  products,  in
particular  the combinations that  work synergistically through one or  multiple  pathways
of  cholesterol  homeostasis.  Recent  studies  on the combination of  the plant  alkaloid ber‐
berine and plant  sterols/stanols  have shown an excellent  example of  this  approach.  The
researchers  have  demonstrated  consistently  that  plant  sterols  or  stanols  and  berberine
have  a  moderate  effect  to  lower  blood  cholesterol  levels  in  different  animal  models.
However,  when plant  sterols/stanols  were combined with berberine,  a  significant  syner‐
gism was produced. They remarkably improved cholesterol-lowering efficacy by synerg‐
istically inhibiting cholesterol absorption [90,91].
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11. Conclusions
Cardiovascular disease has long been the lead cause of mortality and morbidity in the
developed countries and similar situation has arisen in recent years in the developing coun‐
tries. The increased prevalence of CVD is due to the significantly improved food supply and
processing and rapid shift of lifestyle from active to sedentary nature, resulting increased
incidence of obesity and overweight. Although the development and clinical use of statin
drugs and other cholesterol-lowering drugs has been stabilize the mortality resulted from CVD
since last decade, the incidence has been stably rising. According, the control of risk factors
for atherosclerosis and CVD remains critical. The primary risk factor is hypercholesterolemia.
There still exists a strong demand to develop novel products, especially from distinct choles‐
terol metabolic pathways or molecular targets and from different new approaches as men‐
tioned above. It is optimistic that in the near future, new cholesterol-lowering products, either
drugs or natural products with higher efficacies, better specificity and better safe profiles will
be developed.
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